THERANOSTICS INSIGHTS

Rhenium Skin Cancer Therapy



Radioisotope

Re-188, Rhenium-188 post-transition metals $T \frac{1}{2}$: 16,9 h

Use

Non-melanoma skin cancer (NMSC) of the basal and squamous cell types.

Production

Tungsten/Rhenium Generator W-188/Re-188

Radiation

Beta particles (β -)

Target/Mechanism


The Re-188 nanocolloid emits (β -) radiation. When applied to the lesion, radiation has a local, direct action, leading to cell death. At the same time, the immune system is activated, leading to a reaction that results in the wound healing.

Insight

The group led by Dr Cipriani (Hospital S. Eugênio - Italy) and Dr Sedda (ENEA-Italy) developed a nanocolloid containing Re-188 to be used in epidermal radioisotope therapy.

Since 2014, it is an approved therapy for the treatment of basal cell carcinoma (BCC) and squamous cell carcinoma (SCC).

It used in Europe, South Africa and Australia, mainly in cases of difficult, disfiguring or mutilating surgery.





Lesion area to be treated



Application of Rhenium-SCT, treatment time 45 – 180 min



Healing process 30 - 180 days